Cargando…

An epigenomic approach to therapy for tamoxifen-resistant breast cancer

Tamoxifen has been a frontline treatment for estrogen receptor alpha (ERα)-positive breast tumors in premenopausal women. However, resistance to tamoxifen occurs in many patients. ER still plays a critical role in the growth of breast cancer cells with acquired tamoxifen resistance, suggesting that...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feng, Qin, Zhang, Zheng, Shea, Martin J, Creighton, Chad J, Coarfa, Cristian, Hilsenbeck, Susan G, Lanz, Rainer, He, Bin, Wang, Lei, Fu, Xiaoyong, Nardone, Agostina, Song, Yongcheng, Bradner, James, Mitsiades, Nicholas, Mitsiades, Constantine S, Osborne, C Kent, Schiff, Rachel, O'Malley, Bert W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4085766/ https://www.ncbi.nlm.nih.gov/pubmed/24874954 http://dx.doi.org/10.1038/cr.2014.71

Ejemplares similares

Pathway-Centric Integrative Analysis Identifies RRM2 as a Prognostic Marker in Breast Cancer Associated with Poor Survival and Tamoxifen Resistance()()()
por: Putluri, Nagireddy, et al.
Publicado: (2014)

High-throughput approaches to discover novel immunomodulatory agents for cancer
por: McMillin, Douglas W., et al.
Publicado: (2012)

SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of cMYC oncoprotein
por: Geng, Chuandong, et al.
Publicado: (2017)

The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance
por: Nardone, Agostina, et al.
Publicado: (2018)

Multimodal action of ONECUT2 in driving neuroendocrine prostate cancer
por: Kaochar, Salma, et al.
Publicado: (2019)

ICG-001 Exerts Potent Anticancer Activity Against Uveal Melanoma Cells
por: Kaochar, Salma, et al.
Publicado: (2018)

Clinical appraisal of abiraterone in the treatment of metastatic prostatic cancer: patient considerations, novel opportunities, and future directions
por: Bedoya, Diego J, et al.
Publicado: (2013)

Steroid Receptor Coactivator-2 Controls the Pentose Phosphate Pathway through RPIA in Human Endometrial Cancer Cells
por: Szwarc, Maria M., et al.
Publicado: (2018)

From transcriptional regulation to drugging the cancer epigenome
por: Bradner, James E
Publicado: (2014)

Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer
por: Creighton, Chad J, et al.
Publicado: (2010)

Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions
por: Mahaweni, Niken M., et al.
Publicado: (2018)

Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy
por: Richardson, Paul, et al.
Publicado: (2010)

Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase
por: Fu, Xiaoyong, et al.
Publicado: (2014)

Epigenomic footprints across 111 reference epigenomes reveal tissue-specific epigenetic regulation of lincRNAs
por: Amin, Viren, et al.
Publicado: (2015)

Mitochondrial pyruvate import is a metabolic vulnerability in androgen receptor-driven prostate cancer
por: Bader, David A., et al.
Publicado: (2018)

Incidental detection of FGFR3 fusion via liquid biopsy leading to earlier diagnosis of urothelial carcinoma
por: Huang, Quillan, et al.
Publicado: (2023)

A scoring system for the follow up study of nuclear receptor coactivator complexes
por: Han, Sang Jun, et al.
Publicado: (2006)

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anti-cancer drug activity
por: McMillin, Douglas W., et al.
Publicado: (2010)

The Treatment of Multiple Myeloma Patients Not Eligible for Asct
por: Richardson, Paul, et al.
Publicado: (2010)

A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast Cancer
por: Thangavel, Hariprasad, et al.
Publicado: (2019)

Reprogramming of the estrogen responsive transcriptome contributes to tamoxifen-dependent protection against tumorigenesis in the p53 null mammary epithelial cells
por: Palaniappan, Murugesan, et al.
Publicado: (2018)

Sequentiality and processivity of nuclear receptor coregulators in regulation of target gene expression
por: O'Malley, Bert W.
Publicado: (2003)

Cellular proteome, coregulators, endocrine system and the human brain: the Regulatory biology of humanism
por: O'Malley, Bert W.
Publicado: (2011)

SRC-2 Coactivator: a role in human metabolic evolution and disease
por: O’Malley, Bert W.
Publicado: (2020)

Epigenome environment interactions accelerate epigenomic aging and unlock metabolically restricted epigenetic reprogramming in adulthood
por: Treviño, Lindsey S., et al.
Publicado: (2020)

Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)

Analysis of interactions between the epigenome and structural mutability of the genome using Genboree workbench tools
por: Coarfa, Cristian, et al.
Publicado: (2014)

Stem Cell Implants for Cancer Therapy: TRAIL-Expressing Mesenchymal Stem Cells Target Cancer Cells In Situ
por: Reagan, Michaela R., et al.
Publicado: (2012)

Pash 3.0: A versatile software package for read mapping and integrative analysis of genomic and epigenomic variation using massively parallel DNA sequencing
por: Coarfa, Cristian, et al.
Publicado: (2010)

Racial disparities in prostate cancer: A complex interplay between socioeconomic inequities and genomics
por: Lowder, Dallin, et al.
Publicado: (2022)

Endocrinology and hormone therapy in breast cancer: New insight into estrogen receptor-α function and its implication for endocrine therapy resistance in breast cancer
por: Schiff, Rachel, et al.
Publicado: (2005)

The Medical Research Council Myeloma IX trial: the impact on treatment paradigms*
por: Richardson, Paul G, et al.
Publicado: (2012)

Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease
por: Dowling, Paul, et al.
Publicado: (2014)

Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma
por: Laubach, Jacob P., et al.
Publicado: (2021)

Comparative and integrative analysis of transcriptomic and epigenomic-wide DNA methylation changes in African American prostate cancer
por: Creighton, Chad J., et al.
Publicado: (2023)

Mechanisms of enhancer action: the known and the unknown
por: Panigrahi, Anil, et al.
Publicado: (2021)

β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib
por: Huang, Catherine, et al.
Publicado: (2011)

Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers -- role of estrogen receptor and HER2 reactivation
por: Wang, Yen-Chao, et al.
Publicado: (2011)

In Memoriam, P. Michael Conn, PhD (1949–2016)
por: O'Malley, Bert W., et al.
Publicado: (2017)

90 Years of progesterone: Ninety years of progesterone: the ‘other’ ovarian hormone
por: Ali, Simak, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_h9anje2ui0fasilud06bj3lgqu